On this page
Evaluate the evidence before choosing a profile
Four practical guides turn a trial headline into a checkable evidence trail.
Clinical-trial phases
What Phase 1 to 4 can—and cannot—establish.
Registry records
Decode status, outcomes, dates, versions and posted results.
Press release vs paper
Use seven checks for sponsor topline claims.
Weight-loss trials
Read comparators, estimands, missing data and safety.
A structured evidence library for peptides, metabolic therapeutics and related biotechnology. Each profile separates human evidence from animal and laboratory findings, identifies regulatory status, and links to primary sources wherever possible.
Start with the question you came to answer
Is “GLP-3” a real medicine?
Read the terminology guide to distinguish an internet nickname from the GIP, GLP-1 and glucagon receptor systems. Then check the retatrutide trial tracker for published evidence versus sponsor-reported results.
What has the TGA actually said?
Use our source-led alert briefing for the 14 September 2026 retatrutide case. The TGA found semaglutide and no retatrutide in one tested product; the finding does not describe every vial sold under that name. Read the regulator’s notice.
How strong is a peptide claim?
Check the evidence level, population, study design and outcome. Start with what trial phases mean and how a sponsor announcement differs from a full paper. A mechanism observed in a cell cannot establish a clinical benefit.
What does a laboratory result prove?
Read how to interpret an HPLC chromatogram and what identity and purity tests cannot establish. Neither a purity percentage nor a certificate alone demonstrates sterility or clinical safety.
How to read a profile
- Identity: Confirm the exact molecule and its aliases. Similar names can refer to different substances.
- Evidence: Look for controlled human results first, then separate observational, animal and cell findings.
- Status: Check the date and the relevant Australian authority record. Trial progress, scheduling and ARTG inclusion are separate facts.
- Limits: Read what the cited source does not establish, especially where online claims go beyond the study.
The former catalogue URLs remain available as educational profiles. They contain no prices or purchasing path. This library is organised for readers checking scientific and regulatory claims, not for obtaining substances.
Featured research profiles
CJC-1295 + Ipamorelin
Side-by-side human evidence, FDA safety concerns, Australian Schedule 4 context and the 2026 WADA rules—with combination claims tested against the actual studies.
Ipamorelin
Human pharmacology, the postoperative-ileus trial, FDA compounding concerns and the gap between growth-hormone release and wellness claims.
CJC-1295 “No DAC” terminology
Explains why the market label is not interchangeable with long-acting CJC-1295 evidence, and what is missing for the popular combination.
DSIP and sleep
Maps the small 1980s human sleep studies, the weak chronic-insomnia result and the absence of modern clinical validation.
SLU-PP-332
A preclinical small molecule—not a peptide—studied in mouse endurance and metabolic models, with no established human efficacy.
Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist in Phase 3 development. Includes peer-reviewed Phase 2 results, 2026 Phase 3 topline data and current TGA status.
GHK-Cu
Copper-binding tripeptide studied in tissue remodelling, skin biology and wound research. Human evidence is separated from broader preclinical claims.
MOTS-c
Mitochondrial-derived peptide investigated in metabolism, exercise biology and cellular stress signalling.
AOD-9604
Modified growth-hormone fragment with a historical clinical-development programme in obesity research.
Tesamorelin
Growth-hormone-releasing hormone analogue with human clinical evidence and approved medical use in specific jurisdictions and indications.
Kisspeptin
Neuropeptide central to reproductive endocrinology, with a growing body of controlled human research.
PT-141 / Bremelanotide
Phase 3 evidence, the narrow US-approved indication, safety warnings and limits of extrapolating to unapproved online products.
Melanotan II / MT2
Schedule 4 in Australia with no ARTG product. Covers the small human tanning studies, mole and melanoma uncertainty, serious case reports and current TGA enforcement.
NAD+, NR and NMN
NAD+ is a coenzyme, not a peptide. This profile separates core biology and biomarker movement from unproven anti-ageing claims, compares oral precursors with IV evidence, and explains current TGA rules.
Explore by evidence question
What has been tested in humans?
Profiles prioritise randomised trials, prospective human studies, systematic reviews and registered clinical trials. Preclinical evidence is labelled separately.
What is still experimental?
Investigational status is stated prominently. Mechanistic plausibility is not presented as proof of clinical benefit.
What is the Australian regulatory position?
Where relevant, profiles link directly to TGA warnings, ARTG context and Australian advertising or supply rules.
How is peptide identity measured?
Our Laboratory Science section explains HPLC, LC–MS, purity, identity, stability and analytical limitations.
Research standards
Every substantive profile is designed around the same editorial framework: define the molecule, explain the mechanism, rank the evidence, summarise human data, separate uncertainty from established findings, state regulatory status, and provide primary references. Pages are updated when material new evidence or regulatory decisions become available.
Read our Editorial Policy, Corrections Policy and Advertising & Monetisation Policy.
Elite Peps Australia is a knowledge-only publication. Content is educational and is not medical advice, prescribing guidance or an invitation to obtain or use unapproved therapeutic goods.